Source: Eur Respir Rev 2014; 23: 30-35



Rating:

Share or cite this content

Citations should be made in the following way:
El-Chemaly, Souheil and Henske, Elizabeth P.. Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer. Eur Respir Rev 2014; 23: 30-35

Member's Comments

No comment yet.

Related content which might interest you: Questions on the surveillance of COPD: lessons from cancer Source: ISSN=ISSN 1810-6838, ISBN=, page=192 Year: 2005 Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing? Source: Eur Respir J 2014; 44: 1011-1022 Year: 2014 The clinical benefit of personalised medicine in lung cancer Source: International Congress 2014 – Understanding the benefit of current personalised medicine platforms Year: 2014 Surgery of lung cancer in elderly patients: lessons learned Source: Annual Congress 2008 - Treatment of thoracic tumours Year: 2008 Bronchiectasis: new therapies and perspectives Source: International Congress 2018 – Bronchiectasis: new insights in diagnosis and treatment Year: 2018 PG1 Re-defining the role of chest physicians in lung cancer:ÿnew opportunities in diagnostics and therapy Source: Milan 2017 - Educational material Year: 2017 Targeted therapies for lung cancer: how did the game begin? Source: Breathe 2016; 12: 177-179 Year: 2016 Novel aspects in lung cancer pathology: how does it help for selecting chemotherapy? Source: Annual Congress 2010 - PG4 Core Curriculum Postgraduate Course: Pathology for the clinician Year: 2010 A palliative benefit from chemotherapy - has it impact on symptoms control in the management of metastatic blastoma pulmonum? Case report Source: Eur Respir J 2002; 20: Suppl. 38, 466s Year: 2002 Single-institution experience of the combined operations in management of lung cancer: Lessons learned Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts Year: 2013 Is bronchoscopic photodynamic therapy a therapeutic option in lung cancer? Source: Eur Respir J 2003; 22: 535-541 Year: 2003 New treatment concepts in stage IV non-small cell lung cancer: personalised multidisciplinary approaches Source: Virtual Congress 2021 – Thoracic oncology Year: 2021 What is the scientific and clinical rationale? Triple therapy in COPD patients Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what? Year: 2021 CC3 Lung cancer: personalised treatment and palliative care  Source: Paris 2018 - Educational material Year: 2018 Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019 Endpoints in IPF and lung cancer trials: controversies and perspectives Source: Research Seminar 2015 Year: 2015 Combination immunotherapy in mesothelioma: managing expectations and new toxicities Source: Virtual Congress 2021 – Lung cancer grand round Year: 2021 Induction chemotherapy before lung cancer resection: experiences and perspectives Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004